Evidence map›Paper›PMID 35268652›Full record

ArticleMolecules (Basel, Switzerland)2022

Synthesis and Evaluation of

James M Kelly, Thomas M Jeitner, Nicole N Waterhouse, Wenchao Qu, Ethan J Linstad, Banafshe Samani, Clarence Williams, Anastasia Nikolopoulou, Alejandro Amor-Coarasa, Stephen G DiMagno and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

James M KellyMolecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, NY 10065, USA.
Thomas M JeitnerMolecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, NY 10065, USA.
Nicole N WaterhouseCitigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-9574-7796
Wenchao QuCitigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY 10021, USA.
Ethan J LinstadDepartments of Medicinal Chemistry & Pharmacognosy and Chemistry, University of Illinois-Chicago, Chicago, IL 60612, USA.
Banafshe SamaniDepartments of Medicinal Chemistry & Pharmacognosy and Chemistry, University of Illinois-Chicago, Chicago, IL 60612, USA.
Clarence WilliamsMolecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, NY 10065, USA.
Anastasia NikolopoulouMolecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, NY 10065, USA.
Alejandro Amor-CoarasaMolecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-6793-6765
Stephen G DiMagnoDepartments of Medicinal Chemistry & Pharmacognosy and Chemistry, University of Illinois-Chicago, Chicago, IL 60612, USA.
John W BabichMolecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, NY 10065, USA.
Citigroup · USCornell University · USUniversity of Illinois Chicago · USUniversity of Nebraska–Lincoln · US

Funding

Radiolabeled FASN Inhibitors for PET ImagingR21CA213157 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BABICH, JOHN W · 2017 to 2018
$406k
NCI NIH HHS 1R21CA213157
6 · The paper itself

Abstract

Cancer cells require lipids to fulfill energetic, proliferative, and signaling requirements. Even though these cells can take up exogenous fatty acids, the majority exhibit a dependency on de novo fatty acid synthesis. Fatty acid synthase (FASN) is the rate-limiting enzyme in this process. Expression and activity of FASN is elevated in multiple cancers, where it correlates with disease progression and poor prognosis. These observations have sparked interest in developing methods of detecting FASN expression in vivo. One promising approach is the imaging of radiolabeled molecular probes targeting FASN by positron emission tomography (PET). However, although [

Indexed as

Carbon RadioisotopesPositron-Emission TomographyTriazolesAnimalsCell Line, TumorFatty Acid SynthasesHumansMaleMiceMolecular ProbesProstatic NeoplasmsRadiopharmaceuticalsCarbon-11Carbon RadioisotopesFatty Acid SynthasesMolecular ProbesRadiopharmaceuticalsTriazolescancer metabolismcarbon-11fatty acid synthasepositron emission tomography

Identifiers

PMID35268652
PMCPMC8911806
OpenAlexW4214642182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.